ES2197003B1 - Nuevos compuestos antagonistas de integrinas alfa. - Google Patents

Nuevos compuestos antagonistas de integrinas alfa.

Info

Publication number
ES2197003B1
ES2197003B1 ES200200805A ES200200805A ES2197003B1 ES 2197003 B1 ES2197003 B1 ES 2197003B1 ES 200200805 A ES200200805 A ES 200200805A ES 200200805 A ES200200805 A ES 200200805A ES 2197003 B1 ES2197003 B1 ES 2197003B1
Authority
ES
Spain
Prior art keywords
integrinas
alfa
antagonist compounds
new
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200200805A
Other languages
English (en)
Other versions
ES2197003A1 (es
Inventor
Elena Carceller Gonzalez
Jorge Salas Solana
Cristina Alvarez Farrerons
Juan Andres Andreu Aranza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noucor Health SA
Original Assignee
J Uriach y Cia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200200805A priority Critical patent/ES2197003B1/es
Application filed by J Uriach y Cia SA filed Critical J Uriach y Cia SA
Priority to CA002477943A priority patent/CA2477943A1/en
Priority to EP03727281A priority patent/EP1495044A1/en
Priority to JP2003582179A priority patent/JP2006506320A/ja
Priority to PCT/EP2003/003635 priority patent/WO2003084984A1/en
Priority to AU2003233958A priority patent/AU2003233958A1/en
Priority to ARP030101227A priority patent/AR039401A1/es
Priority to MXPA04008990A priority patent/MXPA04008990A/es
Priority to US10/510,626 priority patent/US20050143391A1/en
Priority to KR10-2004-7015916A priority patent/KR20040094912A/ko
Priority to BR0309120-1A priority patent/BR0309120A/pt
Publication of ES2197003A1 publication Critical patent/ES2197003A1/es
Priority to NO20044330A priority patent/NO20044330L/no
Application granted granted Critical
Publication of ES2197003B1 publication Critical patent/ES2197003B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Nuevos compuestos antagonistas de integrinas alfa. La presente invención se refiere a nuevos compuestos de fórmula I y sus sales, solvatos y prodrogas, en donde los significados de los distintos sustituyentes son como se indican en la parte descriptiva. Estos compuestos son útiles como antagonistas de integrinas alfa.
ES200200805A 2002-04-08 2002-04-08 Nuevos compuestos antagonistas de integrinas alfa. Expired - Fee Related ES2197003B1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ES200200805A ES2197003B1 (es) 2002-04-08 2002-04-08 Nuevos compuestos antagonistas de integrinas alfa.
US10/510,626 US20050143391A1 (en) 2002-04-08 2003-04-08 Heterocyclic amides with alpha-4 integrin antagonist activity
JP2003582179A JP2006506320A (ja) 2002-04-08 2003-04-08 α４インテグリン拮抗薬活性を有する新規化合物
PCT/EP2003/003635 WO2003084984A1 (en) 2002-04-08 2003-04-08 Heterocyclic amides with alpha-4 integrin antagonist activity
AU2003233958A AU2003233958A1 (en) 2002-04-08 2003-04-08 Heterocyclic amides with alpha-4 integrin antagonist activity
ARP030101227A AR039401A1 (es) 2002-04-08 2003-04-08 Un compuesto antagonista de integrinas alfa 4 y un procedimiento para preparar el mismo
CA002477943A CA2477943A1 (en) 2002-04-08 2003-04-08 Heterocyclic amides with alpha-4 integrin antagonist activity
EP03727281A EP1495044A1 (en) 2002-04-08 2003-04-08 Heterocyclic amides with alpha-4 integrin antagonist activity
KR10-2004-7015916A KR20040094912A (ko) 2002-04-08 2003-04-08 알파-4 인테그린 안타고니스트 활성을 갖는 헤테로시클릭아미드
BR0309120-1A BR0309120A (pt) 2002-04-08 2003-04-08 Compostos com atividade antagonista de integrina alfa4
MXPA04008990A MXPA04008990A (es) 2002-04-08 2003-04-08 Amidas heterociclicas con actividad antagonista de (4 integrinas.
NO20044330A NO20044330L (no) 2002-04-08 2004-10-12 Heterosykliske amider med alfa-4 intergrin-antagonistaktivitet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200200805A ES2197003B1 (es) 2002-04-08 2002-04-08 Nuevos compuestos antagonistas de integrinas alfa.

Publications (2)

Publication Number Publication Date
ES2197003A1 ES2197003A1 (es) 2003-12-16
ES2197003B1 true ES2197003B1 (es) 2005-03-16

Family

ID=28686084

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200200805A Expired - Fee Related ES2197003B1 (es) 2002-04-08 2002-04-08 Nuevos compuestos antagonistas de integrinas alfa.

Country Status (12)

Country Link
US (1) US20050143391A1 (es)
EP (1) EP1495044A1 (es)
JP (1) JP2006506320A (es)
KR (1) KR20040094912A (es)
AR (1) AR039401A1 (es)
AU (1) AU2003233958A1 (es)
BR (1) BR0309120A (es)
CA (1) CA2477943A1 (es)
ES (1) ES2197003B1 (es)
MX (1) MXPA04008990A (es)
NO (1) NO20044330L (es)
WO (1) WO2003084984A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101273614B1 (ko) 2004-07-08 2013-06-12 엘란 파마슈티칼스, 인크. 중합체 부분을 포함하는 다가 ｖｌａ―４ 길항제
CA2591922A1 (en) * 2004-12-24 2006-06-29 Prosidion Limited G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
WO2006127584A1 (en) 2005-05-20 2006-11-30 Elan Pharmaceuticals, Inc. Imidazolone phenylalanine derivatives as vla-4 antagonists
US8987306B2 (en) 2005-06-07 2015-03-24 The Trustees Of The University Of Pennsylvania Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold
WO2006133338A1 (en) * 2005-06-07 2006-12-14 The Trustees Of The University Of Pennesylvania INHIBITORS OF THE α2β1/GPIa-IIa INTEGRIN
AU2006264651A1 (en) * 2005-06-30 2007-01-11 Prosidion Limited G-protein coupled receptor agonists
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
MX2010006259A (es) * 2007-12-05 2010-08-23 Astrazeneca Ab Piperazinas como agentes antiobesidad.
AU2008333183A1 (en) 2007-12-05 2009-06-11 Astrazeneca Ab (Publ) Piperazine derivatives and their use as leptin receptor modulators
US20090203695A1 (en) * 2007-12-05 2009-08-13 Biovitrum Ab Compounds IV
CA2720164A1 (en) * 2008-03-31 2009-10-08 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
EP3199551A3 (en) 2009-07-31 2017-10-18 E. R. Squibb & Sons, L.L.C. Fully human antibodies to btla
US8691227B2 (en) 2009-12-17 2014-04-08 Merck Sharp & Dohme Corp. Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
CA3019130A1 (en) * 2016-04-01 2017-10-05 The Regents Of The University Of California Inhibitors of integrin alpha 5 beta 1 and methods of use
WO2018085552A1 (en) * 2016-11-02 2018-05-11 Saint Louis University Integrin antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512625A (ja) * 1997-05-29 2002-04-23 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としての複素環アミド化合物
CA2290749A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4
CA2380817A1 (en) * 1999-08-13 2001-02-22 Biogen, Inc. Cell adhesion inhibitors
EP1253923A1 (en) * 2000-01-28 2002-11-06 Biogen, Inc. Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses

Also Published As

Publication number Publication date
ES2197003A1 (es) 2003-12-16
JP2006506320A (ja) 2006-02-23
WO2003084984A1 (en) 2003-10-16
BR0309120A (pt) 2005-01-11
NO20044330L (no) 2004-10-28
MXPA04008990A (es) 2005-06-20
US20050143391A1 (en) 2005-06-30
WO2003084984A8 (en) 2003-12-11
AR039401A1 (es) 2005-02-16
EP1495044A1 (en) 2005-01-12
AU2003233958A1 (en) 2003-10-20
KR20040094912A (ko) 2004-11-10
CA2477943A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
ES2197003B1 (es) Nuevos compuestos antagonistas de integrinas alfa.
ECSP12006041A (es) Derivados de pirazolopiridina
DOP2009000039A (es) COMPUESTOS DE PIRIDO (2,3-D) PIRIMIDINONA Y SU USO COMO INHIBIDORES DE P13-Ka
CY1113657T1 (el) Νεα παραγωγα βενζοφαινονης ή αλατα αυτων
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
ATE372768T1 (de) N-(2-arylethyl) benzylamine als 5-ht6 rezeptor- antagoniste
CY1111671T1 (el) Ετεροκυκλικη ενωση
CY1109656T1 (el) Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης
BRPI0414592A (pt) antagonistas de receptores de trombina
CY1109936T1 (el) Ανταγωνιστες υποδοχεων χυμοκινων
CY1109414T1 (el) Ν-σουλφονυλ πυρρολια και χρηση αυτων ως αναστολεις αποακετυλασης ιστονης
CY1115302T1 (el) Ενωση οξαζολιου και φαρμακευτικη συνθεση
CR8312A (es) Nuevas sulfonamidas como agentes fitosanitarios
CY1113450T1 (el) Διαμινοπυριμιδινες ως ρ2χ3 και ρ2χ2/3 ανταγωνιστες
PE20040636A1 (es) Ester de 2'-c-metil-3'-o-l-valina de ribofuranosilcitidina
CY1113578T1 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
CY1110863T1 (el) Παραγωγα του 2-(8,9-διοξο-2,6-διαζαδικυκλο (5.2.0)-εννε-1(7)-εν-2-υλ)αλκυλ-φωσφονικου οξεος και η χρηση τους ως ανταγωνιστων του ν-μεθυλ- d-ασπαρτικου (nmda) υποδοχεα
SE0202465D0 (sv) New compounds
ECSP024360A (es) Derivados de fenilglicina
ATE325796T1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
TR200402069T4 (tr) Difenilüre türevleri ve bunların alfa 2/5-HT2c antagonisti olarak kullanılması
PA8576001A1 (es) "difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion , medicamentos que comprenden estos compuestos y su uso".
UY27236A1 (es) Inhibidores de pcp basados en ácidos 3-heterociclilpropanohidroxámicos
AR045326A1 (es) Derivados de aminoquinolina y su uso como ligandos a3 de adenosina
ATE517623T1 (de) Verwendung von methylphenidat-derivaten

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20031216

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2197003B1

Country of ref document: ES

FD1A Patent lapsed

Effective date: 20100312